Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

FDA Grants Approval of BMS' Reyataz for Combination Therapy in HIV Treatment

June 23, 2003

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

The Food and Drug Administration approved Bristol-Myers Squibb Co.'s HIV drug Reyataz (atazanavir), indicated to accompany other antiretroviral agents for the treatment of HIV-1 infection.

Reyataz, an azapeptide protease inhibitor, is the first once-daily protease inhibitor approved by the FDA.

Data from Phase II and Phase III studies, which collectively enrolled approximately 2,400 HIV patients, showed that, along with sustained virologic suppression, the drug did not significantly increase cholesterol and triglyceride levels when used in combination therapy.

According to BMS, the recommended dose of Reyataz is 400 mg taken once daily with food in combination with other antiretroviral therapies. The drug will be available in 100-mg, 150-mg and 200-mg doses.

Advertisement
"Reyataz brings unique benefits to people living with HIV/AIDS, including the convenience of once-daily dosing and minimal impact on lipid levels," said Peter Dolan, chairman and chief executive officer of BMS.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by U.S. Food and Drug Administration. Visit the FDA's website to find out more about their activities and publications.
 
See Also
More on HIV Medications
More News and Research on Atazanavir (Reyataz)

Tools
 

Advertisement